nature portfolio

Corresponding author(s):	Francesca Micoli
Last updated by author(s):	2023/06/19

Reporting Summary

Policy information about availability of data

N/A

- A description of any restrictions on data availability

- Accession codes, unique identifiers, or web links for publicly available datasets

- For clinical datasets or third party data, please ensure that the statement adheres to our $\underline{\text{policy}}$

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

5	ιa	τ	S	U	CS

For all statistical a	analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.						
n/a Confirmed							
☐ ☐ The exa	ct sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement						
A staten	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly						
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.						
A descri	A description of all covariates tested						
A descri	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons						
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)						
For null Give P va	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>						
For Baye	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings						
For hier	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes						
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated							
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.							
Software and code							
Policy information about <u>availability of computer code</u>							
Data collection	N/A						
Data analysis Provide a description of all commercial, open source and custom code used to analyse the data in this study, specifying the state that no software was used.							
	ng custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and y encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.						
Data							

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race</u>, ethnicity and <u>racism</u>.

Reporting on sex and gender N/A						
Reporting on race, ethni other socially relevant groupings	Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.) Please provide details about how you controlled for confounding variables in your analyses.					
Population characteristic	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."					
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.					
Ethics oversight	sight Identify the organization(s) that approved the study protocol.					
Note that full information on Field-specifi	the approval of the study protocol must also be provided in the manuscript. Creporting					
Please select the one belo	w that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.					
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences					
For a reference copy of the docur	nent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>					
Life sciences	s study design					
All studies must disclose o	n these points even when the disclosure is negative.					
	be how sample size was determined, detailing any statistical methods used to predetermine sample size OR if no sample-size calculation arrivers.					

Data exclusions

Describe any data exclusions. If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Replication

Describe the measures taken to verify the reproducibility of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.

Randomization

Describe how samples/organisms/participants were allocated into experimental groups. If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why.

Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Me	thods
n/a	Involved in the study	n/a	Involved in the study
\boxtimes	Antibodies	\boxtimes	ChIP-seq
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging
	Animals and other organisms		
\boxtimes	Clinical data		
\boxtimes	Dual use research of concern		
\boxtimes	Plants		

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals	Mice and rabbits
Wild animals	CD1 mice 4-6 weeks; New Zealand white rabbits
Reporting on sex	Female
Field-collected samples	N/A
Ethics oversight	Animal studies were performed in GSK Animal Facility (Siena, Italy) or in Charles River Laboratories (France), in compliance with the relevant guidelines (Italian D.Lgs. n. 26/14 and European directive 2010/63/UE) and the institutional policies of GSK. The animal protocol was approved by the Italian Ministry of Health (AEC project No. 1140/2020-PR, approval date 18/11/2020).

Note that full information on the approval of the study protocol must also be provided in the manuscript.